Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Liver Diseases

Free Subscription 16.02.2026 3 AJR Am J Roentgenol 2 Am J Gastroenterol 1 Biochem Biophys Res Commun 1 BMC Cancer 4 BMC Gastroenterol 1 Cancer 1 Cancer Res 2 Dig Dis Sci 2 Endoscopy 1 Eur J Pediatr 3 Gastroenterology 1 Hepatology 1 Indian J Gastroenterol 1 J Gastroenterol 10 J Gastroenterol Hepatol 5 J Hepatol 2 Lancet 7 PLoS One 2 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. MARKS RM
   A New Piece of the LI-RADS Puzzle: How a Small Modification Would Impact the PPV for Hepatocellular Carcinoma.
   AJR Am J Roentgenol. 2026 Feb 11. doi: 10.2214/AJR.26.34649.
   PubMed        
   
   
2. STUHLFAUT J
   Imaging Diagnosis of Hepatocellular Carcinoma: The Presence of an Enhancing Capsule May Be Equal to Other Major Criteria, Independent of Lesion Size.
   AJR Am J Roentgenol. 2026 Feb 11. doi: 10.2214/AJR.26.34652.
   PubMed        
   
   
3. METWALLI NS, Abd-Elmoniem KZ, Rivera J, Ghanem AM, et al
   MRI-Derived Hepatic Fat Fraction and Stiffness Measurements in Patients With Chronic Liver Disease: A Prospective Comparison Between Vendors and Field Strengths.
   AJR Am J Roentgenol. 2026 Feb 11. doi: 10.2214/AJR.25.34014.
   PubMed        
   
   

   
   Am J Gastroenterol

4. TAPPER EB, Woodrell CD, Rakoski M, Huang R, et al
   Hepatic Encephalopathy is the Key Driver of Symptom Burden in a Longitudinal Cohort of Patients with Advanced Chronic Liver Disease: PAL-LIVER sub-study.
   Am J Gastroenterol. 2026 Feb 13. doi: 10.14309/ajg.0000000000003964.
   PubMed         Abstract available
   
   
5. PATEL N, Silvey S, Bajaj JS
   Vonoprazan Is Associated with Better Liver-Related Outcomes Compared to Proton Pump Inhibitors In Cirrhosis.
   Am J Gastroenterol. 2026 Feb 10. doi: 10.14309/ajg.0000000000003945.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

6. LUO W, Yu M, Zheng C, Li X, et al
   Mitochondrial dysfunction in MASH: Focusing on chronic inflammation and intercellular communication.
   Biochem Biophys Res Commun. 2026;804:153356.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. SEDEMAN M, Christowitz C, de Jager L, Engelbrecht AM, et al
   Correction to: Obese mammary tumour?bearing mice are highly sensitive to doxorubicin?induced hepatotoxicity.
   BMC Cancer. 2026;26:231.
   PubMed        
   
   

   
   BMC Gastroenterol

8. ZHANG Y, Zhang G, Wang X, Ma Y, et al
   A 7-cm inflection point: nonlinear association between maximum tumor diameter and capsular invasion risk after primary liver cancer resection.
   BMC Gastroenterol. 2026;26:114.
   PubMed         Abstract available
   
   
9. YANG K, Yang B, Chen J, Gao L, et al
   Clinicopathological features of hepatobiliary cells in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid.
   BMC Gastroenterol. 2026 Feb 12. doi: 10.1186/s12876-026-04686.
   PubMed         Abstract available
   
   
10. ZHANG W, Peng J, Dai D, Huang C, et al
    SULT1E1 suppresses hepatocellular carcinoma progression via activation of the TGF-beta/SMAD signaling pathway and cell cycle arrest.
    BMC Gastroenterol. 2026 Feb 11. doi: 10.1186/s12876-026-04659.
    PubMed        
    
    
11. YOUSEFI S, Sadeghi-Adl M, Tarashi S, Siadat SD, et al
    Gut microbiota dysbiosis and hepatic inflammation in morphine dependence and withdrawal: insights from a rat model.
    BMC Gastroenterol. 2026 Feb 9. doi: 10.1186/s12876-026-04669.
    PubMed        
    
    

    
    Cancer

12. TAKEDA Y, Imamura H, Ichida H, Yoshioka R, et al
    Re-evaluating the diagnostic value of alpha-fetoprotein for hepatocellular carcinoma in the direct-acting antiviral era.
    Cancer. 2026;132:e70308.
    PubMed         Abstract available
    
    

    
    Cancer Res

13. JO W, Park C, Kim M, Kim CS, et al
    Endotrophin and CD44-Mediated Heterotypic Signaling Mediates Tumor-Stroma Crosstalk and Facilitates Malignant Progression in Hepatocellular Carcinoma.
    Cancer Res. 2026 Feb 11. doi: 10.1158/0008-5472.CAN-25-3657.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

14. LIU Z, Zhang M, Liu C, Zhang H, et al
    Near-Focus Mode Facilitating Underwater ESD for Laterally Spreading Tumor in the Hepatic Flexure of the Colon.
    Dig Dis Sci. 2026 Feb 11. doi: 10.1007/s10620-026-09732.
    PubMed        
    
    
15. LIU JH, Yang JL, Wang R
    Cholangioscopy Combined with Percutaneous Transhepatic Cholangial Drainage Methylene Blue Injection Facilitating Dominant Intrahepatic Duct Stent Placement.
    Dig Dis Sci. 2026 Feb 11. doi: 10.1007/s10620-026-09738.
    PubMed        
    
    

    
    Endoscopy

16. MIWA H, Oishi R, Tsunoda S, Endo K, et al
    Endoscopic ultrasound-guided hepaticogastrostomy using a novel double-lumen cannula designed for a 0.018-inch guidewire.
    Endoscopy. 2026;58.
    PubMed        
    
    
17. ZHU C, Chen Y, Xie J, Cen J, et al
    Tubeless percutaneous transhepatic one-step biliary fistulation combined with choledochoscopic lithotripsy for hepatolithiasis: a case report.
    Endoscopy. 2026;58.
    PubMed        
    
    

    
    Eur J Pediatr

18. SYCZEWSKA M, Janczyk W, Szczerbik E, Kalinowska M, et al
    Gait deviations in adolescent patients with Wilson disease and their possible connections with biochemical markers: preliminary results.
    Eur J Pediatr. 2026;185:130.
    PubMed         Abstract available
    
    

    
    Gastroenterology

19. LUO J
    Machine Learning in Cirrhosis: Moving from Static Admission Risk to Dynamic Decision Support.
    Gastroenterology. 2026 Feb 11:S0016-5085(26)00121.
    PubMed        
    
    
20. TAKEFUJI Y
    Enhancing Inpatient Mortality Prognostication in Cirrhosis Patients Through Machine Learning Techniques.
    Gastroenterology. 2026 Feb 11:S0016-5085(26)00120.
    PubMed        
    
    
21. GIAMOURIS VJ, Grammatikopoulos T
    Response to "The Natural History of Gastroesophageal Varices in Children With Portal Hypertension".
    Gastroenterology. 2026 Feb 10:S0016-5085(26)00119.
    PubMed        
    
    

    
    Hepatology

22. MASSOUDI D, Srivastava A, Dhanasekaran R
    Unraveling the Tapestry: Lessons from multiomics and spatial biology in hepatocellular cancer.
    Hepatology. 2026 Feb 12. doi: 10.1097/HEP.0000000000001716.
    PubMed         Abstract available
    
    

    
    Indian J Gastroenterol

23. SRIVASTAVA A, Mukund A, Baby A, Niraj, et al
    Partial splenic embolization in patients with cirrhosis: Comparison of < 50% versus > 50% infarction strategy.
    Indian J Gastroenterol. 2026 Feb 14. doi: 10.1007/s12664-025-01921.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

24. HUO TI, Ho SY
    Checking the shape of hepatocellular carcinoma: how irregular is irregular?
    J Gastroenterol. 2026 Feb 8. doi: 10.1007/s00535-026-02359.
    PubMed        
    
    

    
    J Gastroenterol Hepatol

25. KOGISO T, Takano S, Ogasawara Y, Taniai M, et al
    Clinical Outcomes of Fontan-Associated Hepatocellular Carcinoma: a Single-Center Retrospective Study.
    J Gastroenterol Hepatol. 2026 Feb 11. doi: 10.1111/jgh.70280.
    PubMed         Abstract available
    
    
26. JOSHI A, Raja HAA, Roy P, Latif F, et al
    Response to Letter to the Editor: Toward Precision Medicine in Portal Hypertension: Insights From the Carvedilol Versus Propranolol Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Feb 13. doi: 10.1111/jgh.70305.
    PubMed        
    
    
27. MOHAMMADPOUR Z, Castrejon Moreno M, Moazzami B, Mudaliar S, et al
    Endoscopic Ultrasound-Guided Coiling Plus Glue Injection Compared With Other Endoscopic Modalities in Managing Gastric Varices: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2026;41:413-428.
    PubMed         Abstract available
    
    
28. FAN JB, Qin LQ, Ding L, Zhang L, et al
    Effects of Piperine on Obese and Lean Nonalcoholic Fatty Liver Disease in Mice.
    J Gastroenterol Hepatol. 2026;41:753-762.
    PubMed         Abstract available
    
    
29. KRISHNAN A, Kadakia KC, Rudnick SR, deLemos AS, et al
    Modern Diets, Metabolic Inequity, and Race-Ethnic Disparities: Unraveling the Associations With MASLD and Cancer Risk.
    J Gastroenterol Hepatol. 2026;41:573-585.
    PubMed         Abstract available
    
    
30. GONZALEZ-GARCIA K, Zertuche-Martinez C, Reyes-Avendano I, Reyes-Jimenez E, et al
    An Integrated Systematic Review and Meta-Analysis From the Bloodstream to Identify Potential Biomarkers for ALD, MASLD, and HCC Without a Viral Background.
    J Gastroenterol Hepatol. 2026;41:502-515.
    PubMed         Abstract available
    
    
31. DENG X, Huang N, Du K, Zhang H, et al
    The Spleen Promotes Liver Sinusoidal Endothelial Cell Angiogenesis by Stimulating the TGFbeta/Smad2/3 Pathway Through GDF15.
    J Gastroenterol Hepatol. 2026;41:774-786.
    PubMed         Abstract available
    
    
32. TANG S, Xie W, Wu Z, Yang J, et al
    LETIM Robustly Predicts Immune Checkpoint Blockade Efficacy for Liver Cancer Patients Using Multiple Immune-Related Genesets.
    J Gastroenterol Hepatol. 2026;41:763-773.
    PubMed         Abstract available
    
    
33. PANG Y, Wang H, Ding L, Chen Y, et al
    Nomogram Predicting Survival in Gastroesophageal Variceal Bleeding Treated With Sclerotherapy and Cyanoacrylate.
    J Gastroenterol Hepatol. 2026;41:705-719.
    PubMed         Abstract available
    
    
34. XU J, Ma H, Yang W, Tu R, et al
    ATF3 Mediates the Immunoregulatory Role of the Tim-3 Pathway in Primary Biliary Cholangitis.
    J Gastroenterol Hepatol. 2026 Jan 15. doi: 10.1111/jgh.70234.
    PubMed         Abstract available
    
    

    
    J Hepatol

35. DESBOEUFS N, Weber A
    Targeting the tumour's Achilles heel: ATR inhibition to exploit a constitutive vulnerability of hepatoblastoma.
    J Hepatol. 2026 Feb 11:S0168-8278(26)00064-4. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
36. CHEN D, Hui Gong, Zhang X
    Targeting MARCO in CASH: Balancing Antitumor Immunity and Hepatic Homeostasis.
    J Hepatol. 2026 Feb 11:S0168-8278(26)00070-X. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
37. RABASCO MENEGHETTI A, Campani C, Roux C, Carrero ZI, et al
    Detection of Esophageal Varices and Prediction of Hepatic Decompensation in Unresectable Hepatocellular Carcinoma using AI: AI Detection of Varices and Decompensation.
    J Hepatol. 2026 Feb 10:S0168-8278(26)00061-9. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
38. QADRI SF, Porthan K, Dufour S, Lehtimaki TE, et al
    Distinct effects of ketogenic and non-ketogenic weight-loss diets on hepatic steatosis and mitochondrial metabolism in MASLD.
    J Hepatol. 2026 Feb 6:S0168-8278(26)00062-0. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
39. NAULT JC, Campani C, Hirsch TZ, Neumann E, et al
    Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.
    J Hepatol. 2026 Feb 5:S0168-8278(26)00055-3. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    

    
    Lancet

40. NOUREDDIN M, Kowdley KV, Odrljin T, Bain G, et al
    Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2026 Feb 5:S0140-6736(25)02276-7. doi: 10.1016/S0140-6736(25)02276.
    PubMed         Abstract available
    
    
41. VALENTI L, Periti G
    Once-monthly efimosfermin for non-cirrhotic MASH.
    Lancet. 2026 Feb 5:S0140-6736(25)02431-6. doi: 10.1016/S0140-6736(25)02431.
    PubMed        
    
    

    
    PLoS One

42. AHMAD I, Khan SA, Abu Bakar M, Shakoor A, et al
    In-silico target prediction and pathway analysis of propranolol as a potential therapeutic agent for hepatocellular carcinoma.
    PLoS One. 2026;21:e0333978.
    PubMed         Abstract available
    
    
43. YANG L, Han Y, Liu L, Jiang X, et al
    EC2Seq2Sql: Patient-trial matching with LLM agents.
    PLoS One. 2026;21:e0341827.
    PubMed         Abstract available
    
    
44. DOGAY US G, Innocenti F, Koc OM, Yumuk VD, et al
    Prevalence of MASLD and fibrosis in Turkey: Results from a multicenter study of at-risk populations.
    PLoS One. 2026;21:e0341214.
    PubMed         Abstract available
    
    
45. XI J, Wang S, Chen J, Law JCS, et al
    Exploration and discovery of treatment targets for primary biliary cholangitis based on plasma and cerebrospinal fluid proteomics: A multicenter mendelian randomization study.
    PLoS One. 2026;21:e0340166.
    PubMed         Abstract available
    
    
46. KINNUNEN SM, Eloranta K, Pihlajoki M, Valimaki MJ, et al
    GATA4-targeted compounds induce apoptosis and diminish viability of hepatoblastoma cells.
    PLoS One. 2026;21:e0342565.
    PubMed         Abstract available
    
    
47. MAKSOUD Z, Kohler M, Nacul Mora G, Mollmann F, et al
    Comparison of general anesthesia versus no anesthesia in elective transjugular intrahepatic portosystemic shunt (TIPS): Procedural and hemodynamic parameters.
    PLoS One. 2026;21:e0341437.
    PubMed         Abstract available
    
    
48. GAO H, He Z, Yang S, Wang X, et al
    MicroRNA-488-3p-loaded engineered exosomes inhibit proliferation, migration and invasion of hepatocellular carcinoma by targeting SEC61G.
    PLoS One. 2026;21:e0341056.
    PubMed         Abstract available
    
    

    
    Radiology

49. LEWIS S, Wildman-Tobriner B, Cuevas J, Calle S, et al
    Quality of Gadoxetate-enhanced MRI versus US during Hepatocellular Carcinoma Screening in Participants with Cirrhosis.
    Radiology. 2026;318:e251497.
    PubMed         Abstract available
    
    
50. KIM TH, Harding JJ, Chernyak V, Mendiratta-Lala M, et al
    How I Do It: Systemic Therapies for Primary Liver Cancers.
    Radiology. 2026;318:e251371.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum